Similar Posts
Jim Cramer’s 4 stock ideas from JPMorgan Healthcare Conference
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs ,…
Safety plea over co-sleeping baby deaths figures
She added: “It is my sincere hope that by drawing attention to our concerns, prompted by the outcome of our investigations, that the number of baby deaths in which co-sleeping was a preventable factor, can be even further reduced through open conversations about safer sleeping.”
Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in…
Cold weather: What does an unheated room do to your body?
The BBC’s health and science correspondent undergoes an experiment to find out how a cold home affects him.
Ambulances delays lead Wilmslow GPs to drive patient to A&E
Two Wilmslow doctors say the NHS is “broken” after they had to drive a patient to A&E themselves.
These 4 anti-obesity drug stocks could soar, Berenberg says
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs,…